The primary use of this immunoassay is to screen for use of common drugs when there is a suspicion that drug use may be contributing to the clinical picture (e.g. altered mental status, coma).

Due to extensive cross reactivity and the inability of this assay to detect commonly prescribed medications (e.g. hydrocodone) it is not useful for determine patient adherence to therapeutic regimens or potential drug diversion. For this purpose order specific drug tests (e.g. Opiates, urine, quantitative).

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine or therapeutic level of hydromorphone, or hydrocodone. See cross reactivity information below.

This test is not recommended for neonates where there is a question of maternal drug abuse as it is not as sensitive as the Quest drug screen panel in meconium (Quest #30427X: Neonatal Drug Screen, Meconium; required specimen: 5g of meconium).

This test panel screens for the presence of: Amphetamines, Barbiturates, Benzodiazepine, Cocaine (as benzoylecgonine), Cannabinoids, Fentanyl, Methadone, Oxycodone, and Opiates.

Each of the above panel components can be ordered separately.

This testing is performed using immunologic methods therefore these assays may cross-react with similar compounds. For a listing of the cross-reactivities see the test menu entry for the individual drug/metabolite.

Detection Cutoff Limits:

CAUTION!: Presumptive screening test only. Cross reactions and false-positive results may occur within each drug class. However, positive results are NOT routinely confirmed by a second method. If confirmation of the test result is required, it is the responsibility of the physician to separately order a specific confirmatory test for the drug(s) identified. False negative results can also occur in presence of low drug concentrations or drugs/metabolites that do not react in the assay [Click on the name of the drug(s) of interest from the list above for more information].

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine, or for therapeutic concentrations of hydromorphone or hydrocodone. (See cross reactivity information above). If hydrocodone or hydromorphone use is suspected, an opiate confirmation should be ordered from ARUP (test code: OPIQNT). False negative results may also occur as use of synthetic and some semi-synthetic opiates cannot be ruled out by this assay. Specifically, this assay will not detect use of meperidine or tramadol. If use of opiates not detected by this screen is suspected, immunoassay screens can be ordered from ARUP [e.g. meperidine (ARUP#2102288) or tramadol (ARUP#2012297)].

Typical Urine Detection Window after use:

From: Verstraete AG. Detection Times of Drugs of Abuse in Blood, Urine and Oral Fluid. Ther Drug Monit, 26(2) April 2004, 200-205; Kale N.  Urine drug tests: ordering and interpreting results.  Am Fam Physician, 2019 99(1): 33-39.

Results cannot be used for Medico-legal purposes.

Confirmatory testing can be ordered for the specific class of agent found using the test order codes found under the 'Processing' tab of this test menu entry.

Confirmatory testing performed Monday-Friday with a 3-6 day turn around time after receipt by reference laboratory.

See also Drug Screening and individual drug entries.

Refrigerate. If requested freeze excess sample not used for this test for possible confirmatory testing at -20C  

Confirmatory testing can be ordered for the specific class of agent found using the following test order codes:  
 

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine or therapeutic level of hydromorphone, or hydrocodone. See cross reactivity information below.

This test is not recommended for neonates where there is a question of maternal drug abuse as it is not as sensitive as the Quest drug screen panel in meconium (Quest #30427X: Neonatal Drug Screen, Meconium; required specimen: 5g of meconium).

This test panel screens for the presence of: Amphetamines, Barbiturates, Benzodiazepine, Cocaine (as benzoylecgonine), Cannabinoids, Fentanyl, Methadone, Oxycodone, and Opiates.

Each of the above panel components can be ordered separately.

This testing is performed using immunologic methods therefore these assays may cross-react with similar compounds. For a listing of the cross-reactivities see the test menu entry for the individual drug/metabolite.

Detection Cutoff Limits:

CAUTION!: Presumptive screening test only. Cross reactions and false-positive results may occur within each drug class. However, positive results are NOT routinely confirmed by a second method. If confirmation of the test result is required, it is the responsibility of the physician to separately order a specific confirmatory test for the drug(s) identified. False negative results can also occur in presence of low drug concentrations or drugs/metabolites that do not react in the assay [Click on the name of the drug(s) of interest from the list above for more information].

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine, or for therapeutic concentrations of hydromorphone or hydrocodone. (See cross reactivity information above). If hydrocodone or hydromorphone use is suspected, an opiate confirmation should be ordered from ARUP (test code: OPIQNT). False negative results may also occur as use of synthetic and some semi-synthetic opiates cannot be ruled out by this assay. Specifically, this assay will not detect use of meperidine or tramadol. If use of opiates not detected by this screen is suspected, immunoassay screens can be ordered from ARUP [e.g. meperidine (ARUP#2102288) or tramadol (ARUP#2012297)].

Typical Urine Detection Window after use:

From: Verstraete AG. Detection Times of Drugs of Abuse in Blood, Urine and Oral Fluid. Ther Drug Monit, 26(2) April 2004, 200-205; Kale N.  Urine drug tests: ordering and interpreting results.  Am Fam Physician, 2019 99(1): 33-39.

Results cannot be used for Medico-legal purposes.

Confirmatory testing can be ordered for the specific class of agent found using the test order codes found under the 'Processing' tab of this test menu entry.

Confirmatory testing performed Monday-Friday with a 3-6 day turn around time after receipt by reference laboratory.

See also Drug Screening and individual drug entries.

The primary use of this immunoassay is to screen for use of common drugs when there is a suspicion that drug use may be contributing to the clinical picture (e.g. altered mental status, coma).

Due to extensive cross reactivity and the inability of this assay to detect commonly prescribed medications (e.g. hydrocodone) it is not useful for determine patient adherence to therapeutic regimens or potential drug diversion. For this purpose order specific drug tests (e.g. Opiates, urine, quantitative).

Refrigerate. If requested freeze excess sample not used for this test for possible confirmatory testing at -20C  

Confirmatory testing can be ordered for the specific class of agent found using the following test order codes:  
 

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine or therapeutic level of hydromorphone, or hydrocodone. See cross reactivity information below.

This test is not recommended for neonates where there is a question of maternal drug abuse as it is not as sensitive as the Quest drug screen panel in meconium (Quest #30427X: Neonatal Drug Screen, Meconium; required specimen: 5g of meconium).

This test panel screens for the presence of: Amphetamines, Barbiturates, Benzodiazepine, Cocaine (as benzoylecgonine), Cannabinoids, Fentanyl, Methadone, Oxycodone, and Opiates.

Each of the above panel components can be ordered separately.

This testing is performed using immunologic methods therefore these assays may cross-react with similar compounds. For a listing of the cross-reactivities see the test menu entry for the individual drug/metabolite.

Detection Cutoff Limits:

CAUTION!: Presumptive screening test only. Cross reactions and false-positive results may occur within each drug class. However, positive results are NOT routinely confirmed by a second method. If confirmation of the test result is required, it is the responsibility of the physician to separately order a specific confirmatory test for the drug(s) identified. False negative results can also occur in presence of low drug concentrations or drugs/metabolites that do not react in the assay [Click on the name of the drug(s) of interest from the list above for more information].

This test is NOT useful for the detection or monitoring of prescribed opiates such as codeine, or for therapeutic concentrations of hydromorphone or hydrocodone. (See cross reactivity information above). If hydrocodone or hydromorphone use is suspected, an opiate confirmation should be ordered from ARUP (test code: OPIQNT). False negative results may also occur as use of synthetic and some semi-synthetic opiates cannot be ruled out by this assay. Specifically, this assay will not detect use of meperidine or tramadol. If use of opiates not detected by this screen is suspected, immunoassay screens can be ordered from ARUP [e.g. meperidine (ARUP#2102288) or tramadol (ARUP#2012297)].

Typical Urine Detection Window after use:

From: Verstraete AG. Detection Times of Drugs of Abuse in Blood, Urine and Oral Fluid. Ther Drug Monit, 26(2) April 2004, 200-205; Kale N.  Urine drug tests: ordering and interpreting results.  Am Fam Physician, 2019 99(1): 33-39.

Results cannot be used for Medico-legal purposes.

Confirmatory testing can be ordered for the specific class of agent found using the test order codes found under the 'Processing' tab of this test menu entry.

Confirmatory testing performed Monday-Friday with a 3-6 day turn around time after receipt by reference laboratory.

See also Drug Screening and individual drug entries.